In clinical trials
Immune & defense
Murepavadin
Evidence
Clinical trials
Class
Antibacterial peptidomimetic
KEY TAKEAWAY
Murepavadin is a synthetic cyclic peptide designed to kill Pseudomonas aeruginosa by blocking a protein the bacterium needs to build its outer membrane. Murepavadin is not FDA-approved. Phase 3 trials of the intravenous form were halted because of kidney toxicity, and an inhaled version has been in development.
Written by the Veylo editorial team · Updated
November 2026
What it is
Antibacterial peptidomimetic
Being studied for
Studied for Pseudomonas pneumonia
Key fact
Murepavadin is not FDA-approved. Phase 3 trials of the intravenous form were halted because of kidney toxicity, and an inhaled version has been in development.
Route
Intravenous in earlier trials; inhaled in development
Evidence strength
Clinical trials
Murepavadin is a synthetic cyclic peptide designed to kill Pseudomonas aeruginosa by blocking a protein the bacterium needs to build its outer membrane.
It binds LptD, a transporter that places lipopolysaccharide in the bacterial outer membrane, so the cell cannot maintain its protective shell.
Murepavadin is not FDA-approved. Phase 3 trials of the intravenous form were halted because of kidney toxicity, and an inhaled version has been in development.
Studied for Pseudomonas pneumonia.
The intravenous form caused kidney injury in trials.
Murepavadin: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.